Used in research for treating cancers, particularly those driven by dysregulation of the PRMT5 enzyme. It acts as a potent and selective inhibitor of PRMT5, which plays a role in epigenetic regulation of gene expression. By inhibiting PRMT5, the compound can suppress tumor growth in preclinical models of hematologic and solid tumors. It is being investigated in clinical trials for its potential as an anticancer agent, especially in cancers with splicing factor mutations or MTAP deletions, which make tumor cells more dependent on PRMT5 activity. Its application focuses on targeted therapy with the goal of inducing cancer cell death while sparing normal cells.